Physicians' Academy for Cardiovascular Education

20 years clinical use of GP IIb/IIIa receptor antagonists

Sep. 14, 2014


Symposium

20 Years clinical use of GP IIb/IIIa receptor antagonists: What have we learned and where to go?


View Video Presentation 

Recorded at ESC 2014 - September 1, 2014- Barcelona - duration 5 minutes



J. Wouter Jukema, MD, PhD, FESC, FACC, is Professor of Cardiology, an established Clinical Investigator of the Netherlands Heart Foundation, as well as Chairman of “Leiden Vascular Medicine” at Leiden University Medical Center (LUMC) in the Netherlands.

Platelet glycoprotein IIb/IIIa inhibitors (GPI) are antithrombotic agents preventing the binding of fibrinogen to GP IIb/IIIa receptors. Thus, GPI interfere with interplatelet bridging mediated by fibrinogen. Intravenous GPI were introduced in various clinical settings during the 1990s, yielding substantial benefit in the treatment of acute coronary syndromes, particularly during percutaneous coronary interventions. Results of the many randomised trials evidenced the efficacy of this drug class. Indications for the use of GPI have been more restricted in recent years. Nonetheless, GPI may still be beneficial during coronary interventions among high-risk patients including acute ST-elevation and non-ST-elevation myocardial infarctions, particularly in the absence of adequate pretreatment with oral antiplatelet drugs or when direct thrombin inhibitors are not utilised. Intracoronary GPI administration has been suggested as adjunctive therapy during primary percutaneous coronary intervention, and the results of larger ongoing trials are expected to elucidate its clinical potential. This Educational Programme outlines the key milestones of GPI development and provides an up-todate overview of the clinical applicability of these drugs in the era of refined coronary stenting, potent antithrombotic drugs, and novel thrombin inhibiting agents.

 

Start video